Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer

Chest

Volumn 128, Issue 1, 2005, Pages 308-316

  Zheng, Thong ^a   Bepler, Gerold ^a   Cantor, Alan ^a   Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Epidermal growth factor; Non small cell lung cancer; Prognosis; Receptor tyrosine kinase; Tobacco smoking

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TOBACCO; TUMOR VOLUME;

EID: 22244460507     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.1.308     Document Type: Article

References (55)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
2. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:1878-1885
3. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62:6659-6666
4. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53:2379-2385
5. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515-522
6. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996; 7:133-141
7. Rabiasz GJ, Langdon SP, Bartlett JM, et al. Growth control by epidermal growth factor and transforming growth factor-α in human lung squamous carcinoma cells. Br J Cancer 1992; 66:254-259
8. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158
9. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238-3247
10. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246
11. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-6565
12. Kari C, Chan TO, Rocha de Quadros M, et al. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003; 63:1-5
13. Lader AS, Ramoni MF, Zetter BR, et al. Identification of a transcriptional profile associated with in vitro invasion in non-small cell lung cancer cell lines. Cancer Biol Ther 2004; 3:624-631
14. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15:28-32
15. Kanematsu T, Yano S, Uehara H, et al. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 2003; 13:289-298
16. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7:603-607
17. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68:162-165
18. Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004; 10:136-143
19. Mukohara T, Kudoh S, Yamauchi S, et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41:123-130
20. Mukohara T, Kudoh S, Matsuura K, et al. Activated Akt expression has significant correlation with EGFR and TGF-α expressions in stage I NSCLC. Anticancer Res 2004; 24:11-17
21. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-3807
22. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20:975-981
23. Cox G, Louise Jones J, Andi A, et al. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer 2001; 34:417-426
24. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7:1850-1855
25. D'Amico TA, Massey M, Herndon JE II, et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999; 117:736-743
26. Pfeiffer P, Clausen PP, Andersen K, et al. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996; 74:86-91
27. Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995; 31A:178-183
28. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4:241-249
29. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998; 77:663-669
30. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15:2858-2865
31. Pfeiffer P, Nexo E, Bentzen SM, et al. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. Br J Cancer 1998; 78:96-99
32. Dazzi H, Hasleton PS, Thatcher N, et al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer: use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 1989; 59:746-749
33. Hoos A, Stojadinovic A, Singh B, et al. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 2002; 160:175-183
34. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996; 2:1787-1793
35. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003; 41(suppl):S29-S42
36. Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002; 8:54-60
37. Khuri FR. Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. Clin Lung Cancer 2003; 5(suppl):S36-S40
38. Siegfried JM, Weissfeld LA, Luketich JD, et al. The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 1998; 66:1915-1918
39. Bihl M, Tamm M, Nauck M, et al. Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 1998; 19:606-612
40. Song L, Turkson J, Karras JG, et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003; 22:4150-4165
41. Carbone DP. The biology of lung cancer. Semin Oncol 1997; 24:388-401
42. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61:3986-3997
43. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22:2812-2822
44. Janmaat ML, Kruyt FA, Rodriguez JA, et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9:2316-2326
45. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:1103-1109
46. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001; 61:1309-1313
47. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
48. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
49. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311
50. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-1167
51. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98:13790-13795
52. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816-824
53. Huang J, Qi R, Quackenbush J, et al. Effects of ischemia on gene expression. J Surg Res 2001; 99:222-227
54. Yano T, Yazima S, Hagiwara K, et al. Activation of epidermal growth factor receptor in the early phase after renal ischemia-reperfusion in rat. Nephron 1999; 81:230-233
55. Sondeen JL, Dubick MA, Yu Y, et al. Hemorrhage and renal ischemia-reperfusion upregulates the epidermal growth factor receptor in rabbit duodenum. J Lab Clin Med 1999; 134:641-648